Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...

These Catalent sites are already involved in Novo Nordisk manufacturing contracts, which are largely tied to ramping up supply of the firm’s obesity drug Wegovy. Novo Nordisk expects that ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Shares of weight-loss drugmakers like Novo Nordisk and Eli Lilly surged after President Biden proposed expanding anti-obesity drug coverage under state health plans. The move could reduce ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...